ADMA vs DNLI
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ADMA · ADMA Biologics$12.73 ▼ 3.63%
DNLI · Denali Therapeutics$20.07 ▲ 1.77%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ADMA -13.5%
- DNLI +28.7%
Head to head
| Metric | ADMA | DNLI |
|---|---|---|
| Price | $12.73 | $20.07 |
| Change today | ▼ 3.63% | ▲ 1.77% |
| Market cap | $2.82B | $3.22B |
| Return, 3 months | +30.6% | -19.7% |
| Return, year to date | -30.2% | +21.6% |
| Return, 1 year | -12.3% | +33.6% |
| P/E (TTM) | 16.5 | – |
| P/B | 6.4 | 3.5 |
| P/E percentile vs own 5y | 66th | 73rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +2.0% | – |
| Net profit growth (YoY) | +10.5% | -2.8% |
| Gross margin | 64.7% | 97.4% |
| Operating margin | 42.3% | -15,058.2% |
| Net margin | 33.0% | -14,191.2% |
| Return on equity | 41.9% | -54.9% |
| Analyst target vs. price | +17.8% | +79.9% |
| Analyst buy share | 50% | 100% |
| RSI (14) | 66 | 54 |
| 30-day volatility | 79.8% | 46.7% |
| Max drawdown, 1 year | -62.7% | -35.3% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DNLI is the largest of the group by market value.
- DNLI has returned the most over the past year.
- ADMA keeps the most profit per dollar of sales.
- DNLI has been the calmest stock over the last 30 days.